ImmunityBio, Inc., publicly traded under the ticker IBRX on NASDAQ, experienced a notable surge in share price on Thursday, attributed to solid execution and expanding sales volume of its cancer immunotherapy product, Anktiva. The company revealed preliminary figures indicating a significant leap in net product revenue for fiscal 2025, highlighting the ongoing commercial momentum behind its offerings.
For fiscal year 2025, ImmunityBio recorded preliminary net product revenue of approximately $113 million from Anktiva sales. This result represents a remarkable 700% increase compared to the prior year, underscoring substantial growth in market adoption. Anktiva is distinguished as the first immunotherapy approved by the U.S. Food and Drug Administration (FDA) specifically designed to treat non-muscle invasive bladder cancer carcinoma in situ (CIS).
In the fourth quarter of 2025, the firm's revenue from Anktiva alone reached nearly $38.3 million, outperforming the third quarter's $31.8 million. This quarter-over-quarter increase of roughly 20% also equates to an impressive 431% rise year-over-year, signaling expanding commercial traction. The company additionally reported that unit sales volume for Anktiva surged by approximately 750% in 2025 relative to 2024.
Reflecting on these results, Richard Adcock, President and Chief Executive Officer of ImmunityBio, stated, "We delivered strong quarter-over-quarter revenue growth, reflecting accelerating adoption of Anktiva and the continued execution of our commercial strategy." He emphasized that the company remains committed to advancing its market penetration and expanding patient access to its therapies.
Financially, ImmunityBio ended the recent quarter with an estimated cash position totaling nearly $242.8 million, which encompasses cash, cash equivalents, and marketable securities. This level of liquidity provides a solid foundation to support ongoing research initiatives and commercial development activities.
On the clinical front, ImmunityBio has recently shared data from its Anktiva (nogapendekin alfa inbakicept) program targeting non-small cell lung cancer. These findings derive from two studies, QUILT-2.023 and QUILT-3.055, analyzing 151 patients across first-line, second-line, and later-line treatment settings. The data demonstrated statistically significant restoration of immune function and a consistent positive relationship between lymphocyte recovery and improved survival among patients previously treated with checkpoint inhibitors, reinforcing the therapeutic potential of Anktiva across multiple cancer indications.
From a market perspective, ImmunityBio's stock is displaying strong momentum. It is currently trading approximately 67.1% above its 20-day simple moving average (SMA) and about 58.7% above the 100-day SMA, indicating robust short-term price strength. Over the past year, shares have appreciated 55.44% and are positioned closer to their 52-week high than their low, reflecting sustained investor optimism.
Technical analysis reveals that the Relative Strength Index (RSI) stands at 77.54, placing the stock in overbought territory. This technical signal may caution investors about the potential for a near-term price pullback. However, the Moving Average Convergence Divergence (MACD) indicator remains above its signal line, confirming bullish market sentiment. This combination suggests that while the stock's momentum is strong, some price volatility could emerge.
Analysts appear positive on ImmunityBio's prospects, collectively assigning a Buy rating with an average price target of $13.67. Notably, D. Boral Capital maintains a Buy recommendation with a $24.00 target, while Jefferies has also reiterated a Buy rating and recently raised its price target to $9.00 as of December 12, 2025. This analyst support reflects confidence in the company's growth trajectory and product uptake.
At the time of this report's publication, ImmunityBio shares were trading up approximately 26.16%, with a price near $3.81. Trading metrics suggest strong market interest and highlight the company's ongoing appeal amid investor scrutiny. The stock's key technical resistance level is identified at $4.00; however, no strong support levels have been explicitly specified.
Additionally, the Benzinga Edge scoring system assigns ImmunityBio a momentum score of 70.55 out of 100, signaling that its stock performance is outperforming the broader market. This bullish momentum rating implies a favorable technical setup, potentially attracting investors looking for growth opportunities in the biotechnology and immunotherapy sector.
Overall, ImmunityBio's substantial revenue gains, promising clinical results, healthy cash reserve, and strong technical indicators collectively contribute to the upward trajectory of its stock performance. These factors illustrate the company's advancing position within the competitive immunotherapy market and underscore the importance of its FDA-approved product Anktiva as a commercial driver.